ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

This study has been completed.

Sponsored by: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00046384
  Purpose

The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with acute symptoms of Bipolar Disorder.


Condition Intervention Phase
Bipolar I Disorder
Drug: aripiprazole
Phase III

MedlinePlus related topics:   Bipolar Disorder   

Drug Information available for:   Aripiprazole   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment
  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Patients with acute symptoms of Bipolar Disorder

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00046384

Locations
United States, Arizona
Local Institution    
      Scottsdale, Arizona, United States
United States, Arkansas
Local Institution    
      Little Rock, Arkansas, United States
United States, California
Local Institution    
      Chula Vista, California, United States
Local Institution    
      Pico Rivera, California, United States
Local Institution    
      San Diego, California, United States
Local Institution    
      Riverside, California, United States
United States, District of Columbia
Local Institution    
      Washington, District of Columbia, United States
United States, Florida
Local Institution    
      Winter Park, Florida, United States
United States, New York
Local Institution    
      Staten Island, New York, United States
United States, Oklahoma
Local Institution    
      Oklahoma City, Oklahoma, United States
United States, Tennessee
Local Institution    
      Nashville, Tennessee, United States
United States, Virginia
Local Institution    
      Falls Church, Virginia, United States
United States, Washington
Local Institution    
      Bellevue, Washington, United States
Argentina
Local Institution    
      Mendoza, Argentina

Sponsors and Collaborators
Bristol-Myers Squibb
  More Information


BMS Clinical Trials Disclosure  This link exits the ClinicalTrials.gov site
 
For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   CN138-077
First Received:   September 27, 2002
Last Updated:   June 27, 2008
ClinicalTrials.gov Identifier:   NCT00046384
Health Authority:   United States: Food and Drug Administration

Study placed in the following topic categories:
Bipolar Disorder
Aripiprazole

Additional relevant MeSH terms:
Tranquilizing Agents
Pathologic Processes
Disease
Therapeutic Uses
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Antipsychotic Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers